and prosthetic valve insertion.'0 We report here our experience with the use of bretylium in the treatment of ventricular tachycardia in 25 patients in whom this arrhythmia was resistant to lidocaine and other antiarrhythmic drugs. Furthermore, we report observations that suggest a correlation between the efficacy of bretylium, on the one hand, and the site of the ventricular ectopic focus and the location of myocardial disease, on the other.
Material and Methods Twenty-five patients, 18 men and seven women, with ventricular tachycardia were treated with bretylium (tables 1, 2, and 3). The patients' ages ranged between 30 and 78 years with a mean of 56.8 years. Twenty patients had ischemic heart disease. Of these, 12 developed electrocardiographic changes of a recent myocardial infarction; two had recent ischemia added to old myocardial infarctions; two had only recent ischemia; and four had only old myocardial infarctions. As defined here the term anterior infarction includes anteroseptal, anterior, anterolateral, or lateral myocardial infarction. Of the five remaining patients without ischemic heart disease, one had sarcoid involvement of the lungs and myocardium. Rheumatic heart disease was the primary pathology in two patients, one of whom had undergone operation recently for the insertion of mitral and tricuspid valve prostheses. Lupus We made a distiniction betweeni "repetitive" anid "CCrecurrent" ventricuilar tachiycardia. "Repetitive" ven--tricular tachycardia ( fig. 4) had recent anterior myocardial infarction or ischemia and onie had an old anterior infaretion.
Thus, nine of 20 patients with left ventricular tachycardia did not respond tol bretylium, and two whose arrhythmia did respond went on to die, nevertheless. Eight of these 11 had recent anterior myocardial infarction or ischemia. On the other hand, of ninle patients with left ventricular tachycardia who responded to bretylium and survived, only two had a recent anterior wall infarction. The others had acute inferior infarction in three instances, old infaretions in three, or another disease in one.
The rate of ventricular tachycardia in the 25 patients varied between 118 and 214 beats/min, and the width of the QRS complexes during ventricular tachycardia ranged from 0.12 to 0.24 see. No significant difference was apparent with respect to these variables between right and left ventricuilar tachycardia or between those patients who showed a response to bretylium and those who did not. In addition, no difference in responsiveness Responders and nonresponders to bretylium were equally divided among the six patients taking digoxin. No adverse effects'3 were recognized when bretylium was given in the presence of digitalis.
Dosage
The duration of the ventricular tachyeardias before the institution of bretylium ranged from 75 min to 18 days in the 16 responders, and from 2 hours to 17 days in the nine nonresponders. Twelve patients responded to bretylium beginning with the initial dose; four others responded only after additional doses. The cumulative dose required to produce a favorable response in the 16 patients ranged from 4.3 to 25 mg/kg body weight, the latter within a 6-hour period. The cumulative dose of bretylium given the patients who failed to receive a beneficial effect ranged from 21 to 192 mg/kg, given within 2 hours to 7 days, respectively.
Side Effects
The arterial pressure increased in four patients and decreased in 21. Bretylium had to be discontinued in two instances (patients E. C. and C. C.) because the fall in arterial pressure could not be reversed by administration of fluid or vasopressor drugs, including norepinephrine. Otherwise, symptoms attributed to hypotension occurred only with abrupt changes in posture. Six patients experienced a drop in recumbent systolic arterial pressure below 100 mm Hg while taking the drug. Nausea and vomiting were occasionally present after i.v. but not after im administration. Parotid pain was not produced by the administration of bretylium'4 nor did unexpected changes occur in the laboratory data studied. Patients who had sustained a recent myocardial infarction showed characteristic elevations of serum enzymes.
Discussion
Although bretylium has been shown to be effective in the control of life-threatening ventricular arrhythmias,4 6 our study further defines those clinical situations most likely to respond to this medication. Thus, in our patients whose arrhythmias were potentially lethal and resistant to lidocaine and other antiarrhythmic drugs, we analyzed the electrocardiogram to determine the major site of myocardial disease and to define whether the arrhythmia originated from a focus in the right or left ventricle. 15 Right ventricular tachycardia was associated with inferior myocardial infarction or right ventricular myocardial disease, and a good response to bretylium. Patients with left ventricular tachycardia in the presence of only inferior infarction also responded to bretylium and survived. On the other hand, left ventricular tachycardia that was associated mainly with anterior infarction, mitral regurgitation, and cardiomyopathy exhibited relatively poor responsiveness and a low survival rate.
In our patients, therefore, the site of the ectopic focus during ventricular tachycardia or the location of the myocardial disease, or both, appeared to bear a significant relationship to the patient's course. Since no cases of anterior infarction were associated with right ventricular tachycardia, our data are also compatible with the postulation that the site of infarction determined both the types of tachycardia and the response to bretylium.
Many hemodynamic events have previously been investigated in patients with myocardial infarction.
The changes in certain ones such as preejection period and left ventricular ejection time'6 and the development of cardiogenic shock17 have not been dependent upon the location of infarction.
In contrast, the origin of ectopic ventricular beats has been shown previously to be associated with the location of myocardial infarction,18 and the location of infarction has been related to the incidence of life-threatening ventricular arrhythmias.'9 Benignity of right ventricular ectopic beats as compared to left-sided ones has been suggested in the past.15 These differences in prognosis, taken together with the apparent differences in the responsiveness to 33 Norepinephrine is therefore usually effective in reversing hypotension produced by bretylium. The increase in arterial pressure encountered in some of our patients may be explained by the initial release of norepinephrine from the sympathetic nerve endings,34 before it manifests its blocking action.
In our experience, factors that were not related to the patients' response to bretylium included: (1) Circulation, Volume XLVII, February 1973 duration of the tachyarrhythmia before administration of the drug, and (2) the width and rate of the ectopic QRS complexes during the ventricular tachycardia.
Our studies do not allow us to distinguish between ventricular tachycardias resulting from rapid diastolic depolarization versus those resulting from a reentry mechanism.35 36 Yet, regardless of the underlying mechanism, this study suggests that ventricular tachycardia apparently originating in the right ventricle or associated with inferior infarction responds well to bretylium; left ventricular tachycardia associated with acute anterior myocardial ischemia or infarction does not. In our view, the question of the relationship of drug response to the site of ectopic impulse formation and to the location of myocardial disease merits further clinical and experimental investigation.
